Fazilet Erman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fazilet Erman has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Aslan
Firat University
2 shared publications - Adile Ferda Dagli
Fırat University Faculty of Medicine, Department of Pathology, Elazığ, Turkey
2 shared publications - Ahmet Karataş
Department of Rheumatology, Faculty of Medicine Firat University Elazig Turkey
2 shared publications - Kazim Sahin
Department of Animal Nutrition and Nutritional Disorders, Faculty of Veterinary Medicine, Firat University, Elazig, Türkiye
2 shared publications - Orhan Erman
Department of Biology; Fırat University; Elazığ 23119; Türkiye
2 shared publications - Seda Beyaz
Firat Universitesi
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Archives of Biology and Technology
- Vol. 69
Epigallocatechin-3-Gallate Activates Nrf-2, NF-κB and TNF-α Protein Signaling Pathways in Rat Muscle Tissue Damage
Cisplatin, used as an effective drug in cancer patients, has become a popular topic in studies conducted in recent years. It is known that cisplatin terminates the vital activities of healthy cells as well as cancer cells. Epigallocatechin-3-gallate (EGCG), a member of the catechin group, is a natural antioxidant known to promote and improve health. Catechins, due to their regulatory effect on apoptosis and autophagy, have attracted increasing interest in their positive health effects on various diseases. This study aims to investigate the effect of EGCG on Nrf-2, NF-κB, and TNF-α protein signaling pathways against muscle tissue damage caused by cisplatin. A total of 28 male rats were used in the study, creating 4 groups. The experimental period was 28 days (4 weeks). The protective and healing effects of EGCG against cisplatin-induced damage in muscle tissue were investigated. Catalase (CAT) activity, malonaldehyde (MDA), and glutathione (GSH) levels were measured in a spectrophotometer. Expression levels of Nrf-2, NF-κB, and TNF-α proteins were determined using the Western blot method. When compared to the cisplatin-administered group, MDA levels decreased in the EGCG+Cisplatin-administered group, while CAT activity and GSH levels increased. It was found that EGCG used for therapeutic purposes reduced the expression of Nrf-2, NF-κB, and TNF-α proteins. Histopathological examination showed that muscle tissue damage occurred in the cisplatin group, while the damage decreased in the EGCG+Cisplatin-administered group. Our findings show that EGCG can prevent toxicity due to its anti-inflammatory effect against tissue damage caused by cisplatin.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Archives of Biology and Technology
- Vol. 69
Open AccessEpigallocatechin-3-Gallate Activates Nrf-2, NF-κB and TNF-α Protein Signaling Pathways in Rat Muscle Tissue Damage
Cisplatin, used as an effective drug in cancer patients, has become a popular topic in studies conducted in recent years. It is known that cisplatin terminates the vital activities of healthy cells as well as cancer cells. Epigallocatechin-3-gallate (EGCG), a member of the catechin group, is a natural antioxidant known to promote and improve health. Catechins, due to their regulatory effect on apoptosis and autophagy, have attracted increasing interest in their positive health effects on various diseases. This study aims to investigate the effect of EGCG on Nrf-2, NF-κB, and TNF-α protein signaling pathways against muscle tissue damage caused by cisplatin. A total of 28 male rats were used in the study, creating 4 groups. The experimental period was 28 days (4 weeks). The protective and healing effects of EGCG against cisplatin-induced damage in muscle tissue were investigated. Catalase (CAT) activity, malonaldehyde (MDA), and glutathione (GSH) levels were measured in a spectrophotometer. Expression levels of Nrf-2, NF-κB, and TNF-α proteins were determined using the Western blot method. When compared to the cisplatin-administered group, MDA levels decreased in the EGCG+Cisplatin-administered group, while CAT activity and GSH levels increased. It was found that EGCG used for therapeutic purposes reduced the expression of Nrf-2, NF-κB, and TNF-α proteins. Histopathological examination showed that muscle tissue damage occurred in the cisplatin group, while the damage decreased in the EGCG+Cisplatin-administered group. Our findings show that EGCG can prevent toxicity due to its anti-inflammatory effect against tissue damage caused by cisplatin.
- 2 March 2022
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 32 (6) , 463-476
Ellagic acid inhibits proinflammatory intermediary manufacture by suppressing NF-κB/Akt, VEGF and activating Nrf-2/Caspase-3 signaling pathways in rat testicular damage: a new way for testicular damage cure andin silicoapproach
Ellagic acid (EA) has protective effect on testicular damage and this natural compound decreases oxidative damage. The present study aims to examine the preventive effect of ellagic acid (EA) against carbon tetrachloride (CCl4)-induced testicular tissue damage in rats. In testicular tissue, tumor necrosis factor-α (TNF-α), Nuclear factor erythroid-2 related factor 2 (Nrf-2), B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor (VEGF), Nuclear factor-kappa B (NF-κB), cysteine aspartic proteases (caspase-3) and protein kinase B (Akt) synthesis levels were analyzed by western blot method, reactive oxygen species (ROS) was measured by malondialdehyde (MDA) levels, Glutathione (GSH) level and catalase (CAT) by spectrophotometer. As a result, in comparison with the CCl4 group, caspase-3 and Nrf-2 protein synthesis levels increased in EA + CCl4 group, however, VEGF, Bcl-2, NF-κB, TNF-α and Akt protein synthesis levels decreased, EA application raised GSH levels and CAT activity, reduced MDA levels. In this study, in silico tools were applied to confirm the activity of EA against the cancer with macromolecules such as the above mentioned transcription factors. EA, turned out to show significant activity similarly to some cocrystal ligands, particularly against cancer. These results points out that EA can be used as a testicular damage cure drug in future.
- 2 March 2022
- Published by Taylor & Francis in Toxicology Mechanisms and Methods
- Vol. 32 (6) , 463-476
Ellagic acid inhibits proinflammatory intermediary manufacture by suppressing NF-κB/Akt, VEGF and activating Nrf-2/Caspase-3 signaling pathways in rat testicular damage: a new way for testicular damage cure andin silicoapproach
Ellagic acid (EA) has protective effect on testicular damage and this natural compound decreases oxidative damage. The present study aims to examine the preventive effect of ellagic acid (EA) against carbon tetrachloride (CCl4)-induced testicular tissue damage in rats. In testicular tissue, tumor necrosis factor-α (TNF-α), Nuclear factor erythroid-2 related factor 2 (Nrf-2), B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor (VEGF), Nuclear factor-kappa B (NF-κB), cysteine aspartic proteases (caspase-3) and protein kinase B (Akt) synthesis levels were analyzed by western blot method, reactive oxygen species (ROS) was measured by malondialdehyde (MDA) levels, Glutathione (GSH) level and catalase (CAT) by spectrophotometer. As a result, in comparison with the CCl4 group, caspase-3 and Nrf-2 protein synthesis levels increased in EA + CCl4 group, however, VEGF, Bcl-2, NF-κB, TNF-α and Akt protein synthesis levels decreased, EA application raised GSH levels and CAT activity, reduced MDA levels. In this study, in silico tools were applied to confirm the activity of EA against the cancer with macromolecules such as the above mentioned transcription factors. EA, turned out to show significant activity similarly to some cocrystal ligands, particularly against cancer. These results points out that EA can be used as a testicular damage cure drug in future.
- Open Access
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (4) , 2015-2022
Wnt signaling pathway activities may be altered in primary Sjogren’s syndrome
Sjögren?s syndrome (SS) is an autoimmune disease and its pathogenesis is still not completely clear. The Wingless (Wnt) / ß - catenin pathway has recently been shown to play an important role in inflammation. This study aims to determine the serum and saliva levels of Dickkopf (DKK)1 and sclerostin and evaluate Wnt-1 and Wnt-3a expression in the salivary gland in patients with primary SS Materials and methods:. This study included 30 patients diagnosed with SS, 30 patients diagnosed with systemic lupus erythematosus (SLE), and 29 healthy controls. Serum and saliva levels of DKK1 and sclerostin were measured and the expressions of Wnt1 and Wnt3a in the salivary gland were measured immunohistochemically. Serum DKK1 and sclerostin levels were lower in the SS and SLE groups compared to the control group (both p < 0.001). Saliva DKK1 levels were higher in the SS group compared to the control and SLE groups (p = 0.004 and p = 0.009, respectively). Wnt1 and Wnt3a expression were found in salivary gland tissue samples in 71.4% of primary SS patients and relatively frequent than control group. Serum DKK1 and sclerostin levels in primary SS and SLE were decreased. Moreover, levels of Wnt1 and Wnt3a expression in the salivary gland were also elevated in primary SS. Therefore, it can be concluded that the Wnt / ß - catenin pathway activities may be altered in case of glandular inflammation.
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (4) , 2015-2022
Open AccessWnt signaling pathway activities may be altered in primary Sjogren’s syndrome
Sjögren?s syndrome (SS) is an autoimmune disease and its pathogenesis is still not completely clear. The Wingless (Wnt) / ß - catenin pathway has recently been shown to play an important role in inflammation. This study aims to determine the serum and saliva levels of Dickkopf (DKK)1 and sclerostin and evaluate Wnt-1 and Wnt-3a expression in the salivary gland in patients with primary SS Materials and methods:. This study included 30 patients diagnosed with SS, 30 patients diagnosed with systemic lupus erythematosus (SLE), and 29 healthy controls. Serum and saliva levels of DKK1 and sclerostin were measured and the expressions of Wnt1 and Wnt3a in the salivary gland were measured immunohistochemically. Serum DKK1 and sclerostin levels were lower in the SS and SLE groups compared to the control group (both p < 0.001). Saliva DKK1 levels were higher in the SS group compared to the control and SLE groups (p = 0.004 and p = 0.009, respectively). Wnt1 and Wnt3a expression were found in salivary gland tissue samples in 71.4% of primary SS patients and relatively frequent than control group. Serum DKK1 and sclerostin levels in primary SS and SLE were decreased. Moreover, levels of Wnt1 and Wnt3a expression in the salivary gland were also elevated in primary SS. Therefore, it can be concluded that the Wnt / ß - catenin pathway activities may be altered in case of glandular inflammation.
- 17 August 2014
- Published by Springer Nature in Inflammation
- Vol. 38 (1) , 9-15
Pemetrexed Ameliorates Experimental Arthritis in Rats
Pemetrexed (PMTX) is an anti-folate drug as methotrexate. The purpose of this study was to assess the efficacy of PMTX on collagen-induced arthritis (CIA). Forty Wistar albino rats were randomized into four groups. Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund’s adjuvant. Animals were sacrificed at the 15th day after the onset of arthritis. Tumor necrosis factor alpha (TNF-α), interleukin (IL)-17, and malondialdehyde (MDA) levels were increased, and superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities and the expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) were decreased in the arthritis group. In the PMTX-treated (0.2 and 1 mg/kg/week i.p.) groups, the levels of TNF-α, IL-17, and MDA were decreased; the activities of SOD, CAT, and GPx and the expressions of Nrf2 and HO-1 were restored, and perisynovial inflammation and cartilage–bone destruction were decreased. PMTX has anti-arthritic potential in the CIA model and may be a therapeutic agent for rheumatoid arthritis.
- 17 August 2014
- Published by Springer Nature in Inflammation
- Vol. 38 (1) , 9-15
Pemetrexed Ameliorates Experimental Arthritis in Rats
Pemetrexed (PMTX) is an anti-folate drug as methotrexate. The purpose of this study was to assess the efficacy of PMTX on collagen-induced arthritis (CIA). Forty Wistar albino rats were randomized into four groups. Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund’s adjuvant. Animals were sacrificed at the 15th day after the onset of arthritis. Tumor necrosis factor alpha (TNF-α), interleukin (IL)-17, and malondialdehyde (MDA) levels were increased, and superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities and the expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) were decreased in the arthritis group. In the PMTX-treated (0.2 and 1 mg/kg/week i.p.) groups, the levels of TNF-α, IL-17, and MDA were decreased; the activities of SOD, CAT, and GPx and the expressions of Nrf2 and HO-1 were restored, and perisynovial inflammation and cartilage–bone destruction were decreased. PMTX has anti-arthritic potential in the CIA model and may be a therapeutic agent for rheumatoid arthritis.